Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b lumicitabine trial in hospitalized adults with RSV
NL-OMON47223Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Pharmacokinetics of ALS-008112 and ALS-008144 and RSV RNA viral load AUC to Day 7. Started Dec 2016; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON47223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47223.